Economic Daily News | Reported by Jay Chang
Leadgene Group advances to BIO Asia–Taiwan 2026, uniting the capabilities of its three subsidiary brands to highlight its "One-Stop Biomedical R&D Services."
As the global biomedical industry accelerates into a new era of precision medicine, drug discovery, and cell therapy, the transition from basic research to product development often faces multiple challenges, including cross-stage integration, technology translation, and verification processes. Shortening R&D timelines, reducing cross-organization collaboration costs, and improving R&D efficiency have become critical keys to competitiveness in the biotechnology sector.
At BIO Asia–Taiwan 2026, Leadgene Group joined hands with its three subsidiary brands to showcase its core offering—"One-Stop Biomedical R&D Services." The group comprehensively connects integrated services spanning biological raw materials, cell development platforms, and preclinical research, demonstrating Taiwan's growing strength in transitioning biomedical research into practical applications.
Biomedical R&D is a long and highly precise relay race. Every stage—from in vitro studies and cell culture to preclinical trials—is vital to the final outcome. However, many R&D teams frequently encounter batch-to-batch variations in biological reagents, platform transitions, or handoff issues between different technology suppliers. These friction points can prevent research data from continuing seamlessly, often requiring re-validation and significantly increasing development time and costs.
Yung-Chun Chuang, Chairman of Leadgene Biomedical, stated that many R&D projects stall not because of a deficit in a single technology, but due to a lack of cross-stage integration capabilities, which creates gaps between different nodes in the R&D workflow. Only by effectively linking upstream raw materials, midstream technology platforms, and downstream research validation can R&D efficiency truly be enhanced, thereby accelerating the movement of innovative results toward industrial application.
From biological raw materials and continuous cell monitoring platforms to preclinical trials, Leadgene Group focuses on core technology development, seamlessly connecting the biomedical R&D value chain.
In response to market demands, Leadgene Group has integrated its internal resources to establish a complete service architecture covering various R&D stages. Among its subsidiaries, Leadgene Biomedical has long been dedicated to antibody technology and the development of biological raw materials, providing essential reagents and raw materials required for research. Leadgene Biosolutions focuses on cell line development and process optimization platforms, using intelligent and high-throughput technologies to enhance cell culture efficiency and stability. Leadgene Sidsco offers compliant preclinical research and testing services. Together, they form an all-in-one service model spanning the early, middle, and late stages of research and development.
Yu-Wei Cheng, CEO of Leadgene Biomedical, noted that through the integration of internal resources, the group helps clients seamlessly connect different R&D phases—from in vitro and ex vivo to in vivo research. This ensures a smoother transition during technology translation, reduces cross-platform communication costs, and improves overall R&D efficiency, enabling partners to focus more on core technological innovation.
In addition to demonstrating its integrated service capabilities, Leadgene Biomedical was recently awarded the 22nd "Taiwan Golden Root Award." This honor recognizes the company's long-term dedication to independent R&D and its deep commitment to Taiwan's biotech industry, while highlighting its achievements in actively expanding into international markets. This accolade not only affirms the company's technical and operational performance but also aligns with the theme of this year's BIO Asia: "Global View, Asian Innovation."
Leadgene Biomedical was recently awarded the 22nd "Taiwan Golden Root Award," highly recognizing its business achievements in remaining rooted in Taiwan while keeping a global perspective.
During the exhibition, besides showcasing its comprehensive R&D solutions, Leadgene Group curated the "BioTalk Salon" series. The group invited industry leaders, academic and research institutes, and strategic partners to exchange insights on next-generation precision medicine, biomedical R&D technologies, and industrial applications. Through cross-disciplinary dialogue, the group aims to spark more collaboration opportunities and strengthen the link between innovative technologies and market needs.
Facing rapid global biomedical development and increasingly intense international competition, integrated R&D services are becoming a key pillar supporting new drugs, precision medicine, and biotech innovation. Leadgene Group stated that it will continue to deepen its core technology R&D, reinforce its cross-disciplinary integration capabilities, and join forces with more domestic and international partners to build a more complete biomedical innovation ecosystem—accelerating the entry of more Taiwan-originated R&D achievements into the global market and injecting fresh momentum into global biomedical technology.
